United States Patent 5,278,201: Scope, claim coverage, and US patent landscape for in-situ forming biodegradable thermoplastic implant solutions

Executive summary: US 5,278,201 claims an injectable liquid polymer/solvent system that forms a solid or coagulated biodegradable implant in situ when contacted with body fluid. The core claim scope is defined by (i) a water-insoluble, non-reactive, biodegradable thermoplastic linear polymer (broadly including PLA/PGA/PCL and many other degradable polymers) plus (ii) a water-soluble biocompatible solvent (broadly including NMP, 2-pyrrolidone, DMSO, acetone and multiple organic solvents), with (iii) polymer/solvent concentration “effective to form” an implant upon contact with body fluid. Claims also extend to kits with a delivery device (outlet, ejector, hollow tube) and optional biologically active agents. The claim language is platform-like and design-around risk concentrates on whether a competitor uses the same polymer class, the same general solvation trigger (body fluid contact), and the same “space-filling” in-situ precipitation/coagulation behavior.

What is US Patent 5,278,201 protecting: in-situ forming biodegradable implant compositions and kits?

What is the invention in plain technical claim terms

The patent protects pharmaceutical compositions and pharmaceutical kits that enable in-situ formation of a biodegradable solid/coagulated implant inside a body by injecting or delivering a liquid solution consisting of:

A non-reactive, biocompatible, pharmaceutically acceptable thermoplastic linear polymer that:
- is water-insoluble, and
- is biodegradable by simple or enzymatically catalyzed hydrolysis, and
- has concentration/formulation that is “effective to form” an implant upon contact with body fluid.
A pharmaceutically acceptable biocompatible solvent that is:
- water-soluble, and
- part of a formulation that drives implant formation when mixed with body fluid (solvent diffuses/partitions into aqueous media and polymer precipitates/coagulates/solidifies).

Which claim families matter commercially

Independent composition claim: claim 1 (composition forming solid/coagulated biodegradable implant in situ).
Independent kit claim: claim 9 (kit with polymer/solvent solution plus a device capable of delivering the solution to form implant in situ).

What the claims do not require

No claim text requires:

a specific polymer molecular weight, Tg, crystallinity, or degradation rate profile;
a specific implant shape beyond “solid or coagulated” and later “space filling”;
a specific drug class for the biologically active agent (it is optional and broadly stated).

What are the key claim elements and how broadly do they read in US 5,278,201? (Claims 1, 2, 9)

Claim 1: composition coverage

Claim 1 requires all of the following elements:

Liquid solution for in-situ implant formation in the body.
Thermoplastic linear polymer that is:
- non-reactive, biocompatible, pharmaceutically acceptable,
- water-insoluble,
- biodegradable by simple or enzymatically catalyzed hydrolysis,
- concentration/formulation effective to form an implant in situ upon contacting body fluid.
Water-soluble biocompatible solvent that is pharmaceutically acceptable, with concentration/formulation effective to form the implant in situ when contacting body fluid.

Interpretive impact: Claim 1 is not limited to a single polymer chemistry or a single solvent. Instead it focuses on the combination of a hydrolysable, water-insoluble thermoplastic polymer plus a water-soluble biocompatible solvent, with formulation-dependent precipitation/coagulation in vivo.

Claim 2: polymer genus expansion

Claim 2 narrows claim 1 by specifying polymer selection from an extensive list, including:

polylactides (including PLA and copolymers),
polyglycolides (PGA),
polycaprolactones (PCL),
polydioxannones,
polycarbonates,
polyhydroxybutyrates,
polyalkene oxalates,
polyanhydrides,
polyamides,
polyesteramides,
polyurethanes,
polyacetals,
polyketals,
polyorthocarbonates,
polyphosphazenes,
polyhydroxyvalerates,
polyalkylene succinates,
poly(malic acid),
poly(amino acids),
chitin, chitosan,
polyorthoesters,
and copolymers/terpolymers/mixtures.

Interpretive impact: This is an intentionally broad “consisting essentially of” polymer roster that covers many degradable implant and drug-delivery biomaterials.

Claim 9: kit and delivery device coverage

Claim 9 includes:

A) solution containing the polymer/solvent composition meeting the effective implant-forming criteria, with polymer selection from the same broad genus list.
B) a device containing that solution with:
- an outlet,
- an ejector for expelling the solution through the outlet, and
- a hollow tube fitted to the outlet to insert the solution into a site.

Interpretive impact: Claim 9 is tied to a specific delivery concept: an applicator/ejector system with an outlet and a hollow tube. It can cover syringe-like injection apparatuses and implant delivery devices if they meet the structural elements.

Which polymers and solvents are explicitly listed, and how does that affect freedom-to-operate? (Claims 2–5, 8, 13, 14–15)

Polymer list breadth (Claim 2 and dependent claim carveouts)

Claim 2’s polymer list is the main determinant of breadth. Dependent claims then refine some subsets:

Claim 3: polymer is essentially polylactides, polycaprolactones, and glycolide copolymers.
Claim 8: weight % polymer is about 20% to 75%.
Claim 13: kit polymer is essentially polylactides, polycaprolactones, and glycolide copolymers.

FTO reading: A competitor using PLA/PCL or PLA-co-glycolide type polymers is more likely to land inside Claim 2 (and Claim 3/13 if they align with those subsets). Polymer choices outside hydrolysable thermoplastic families may be a stronger design-around, but Claim 2’s roster is extensive.

Solvent list breadth (Claims 4–5, 14–15)

Claim 4 and Claim 14 list many solvents including:

N-methyl-2-pyrrolidone (NMP),
ethanol,
propylene glycol,
2-pyrrolidone,
acetone,
methyl acetate, ethyl acetate,
methyl ethyl ketone,
dimethylformamide (DMF),
dimethyl sulfoxide (DMSO),
tetrahydrofuran (THF),
caprolactam,
decylmethylsulfoxide,
oleic acid,
and 1-dodecylazacycloheptan-2-one,
plus combinations/mixtures.

Claim 5 and Claim 15 narrow to a smaller set:

NMP, 2-pyrrolidone, DMSO, acetone, plus combinations.

FTO reading: If a product uses NMP or DMSO with hydrolysable water-insoluble thermoplastic polymers to create a precipitating/coagulating implant upon contact with aqueous tissue fluid, it matches the strongest literal pathways.

What “effective to form” means for infringement: precipitation vs coagulation vs solidification triggers

How the claims tie formulation to in vivo formation

Across claim 1 and kit claims, the operative functional language is:

polymer/solvent concentrations and formulas are “effective” to form a solid or coagulated biodegradable implant in situ when the solution contacts body fluid (and “effective to form a space filling implant” in dependent claims).

Practical construction for claim scope

This language supports argument that:

the invention is the functional in-situ phase change driven by body fluid contact, not merely mixing of polymer and solvent.
infringement can focus on whether the delivered liquid solution, as formulated, produces the claimed implant formation mechanism in vivo.

A competitor strategy typically tries to break one of these:

use a non-overlapping polymer class,
use a non-overlapping solvent category (or solvent that is not water-soluble under the claim’s concept),
change the in-situ trigger mechanism (example: crosslinking/cure vs solvent exchange/coagulation), or
change the polymer solubility/instability so that body fluid contact does not yield a “solid or coagulated” biodegradable implant from that polymer.

Where does the “space filling implant” limitation appear, and how might it narrow coverage? (Claims 7, 12, 17, 21)

Dependent claims add “space filling implant”:

Claim 7: composition effective to form a space filling implant when inserted.
Claim 12: kit solution effective to form a space filling implant.
Claim 17: composition likewise.
Claim 21: kit likewise.

Infringement effect: If a competitor’s device forms a localized depot, discrete microspheres, or non-space-filling coagulum, it may argue the dependent limitation is not met. But Claim 1 and Claim 9 do not require “space filling,” so the breadth is still anchored by the main functional “solid/coagulated biodegradable implant” concept.

What additional subject matter is claimed: biologically active agents, drug loading, and kits? (Claims 6, 10, 16, 19)

Optional active-agent claims

Claim 6: composition further comprising an effective amount of a biologically active agent.
Claim 10: kit further comprising biologically active agent dissolved or dispersed within solution.
Claim 16 and 19: mirror these for their respective dependents.

Scope impact: These claims read on drug-loaded implant-forming solutions. Because the “biologically active agent” is not restricted to any therapeutic category, the patent can be implicated by many drug classes if the formulation matches the polymer/solvent system and the in-situ formation mechanism.

What patents are most likely to interact with US 5,278,201: formulation-by-solvent exchange and biodegradable thermoplastic implant delivery?

Without relying on undocumented assertions, the relevant landscape can be structured around three interlocking technology clusters that typically surround this kind of claim:

In-situ forming biodegradable implant platforms (polymer dissolved in a water-miscible solvent; solvent exchange/precipitation in vivo).
Biodegradable hydrolysable polymer compositions (PLA/PGA/PCL and copolymers; hydrolysis-driven degradation).
Injectable/delivery device kits that provide controlled ejection and insertion.

For US 5,278,201 specifically, the claim language indicates the likely closest competitors and inventing parties are those working on:

solvent-exchange in-situ depots using NMP/DMSO/pyrrolidones with PLA/PCL-type polymers,
in-situ forming drug-eluting implants,
and injector/needle delivery systems for polymer-in-solvent compositions.

A competitor’s patent portfolio risk assessment should map:

their polymer family to the explicit “consisting essentially of” list,
their solvent to the explicit water-soluble solvent roster (especially NMP, 2-pyrrolidone, DMSO, acetone),
whether their product produces a solid/coagulated biodegradable implant via body fluid contact (not alternative triggers),
whether their delivery device fits the outlet + ejector + hollow tube kit structure.

How many other claims or dependent limitations materially narrow the patent? (A coverage map)

Material narrowing levers

Claim	Added limitation that narrows scope	Practical effect
2	Polymer must be from broad degradable polymer list	Already broad; mostly confirms core material
3	Polymer limited to polylactides, polycaprolactones, PLA/PGA glycolide copolymers	Narrows within Claim 2 genus
4 / 14	Solvent limited to a longer explicit set	Strong specificity for infringement
5 / 15	Solvent limited to NMP/2-pyrrolidone/DMSO/acetone	Strongest literal match target
7 / 17 / 12 / 21	“Space filling” implant	Narrower dependent coverage
8	Polymer wt% 20-75%	Narrows by formulation range
9	Kit adds delivery device elements	Narrower to systems with outlet/ejector/hollow tube
10 / 19	Active agent dissolved/dispersed in solution	Narrows to drug-loaded variants

Broadest literal routes

For compositions: Claim 1 + Claim 2 (polymer list) without needing solvent subset.
For kits: Claim 9 + the solution/device elements, again with polymer list.

What is the likely patent expiration timing in the US? (exclusivity and enforceability framework)

No filing date, priority date, or term adjustment data is provided here. Therefore the exclusivity timeline cannot be computed accurately for US 5,278,201.

How strong is the patent estate for generic or platform entry: where design-arounds are most likely

Design-around by polymer choice

Claim 2’s list is broad, but an engineered system could still avoid literal coverage by selecting polymer chemistries outside the listed set and outside “biodegradable by simple or enzymatically catalyzed hydrolysis” within the claim’s concept. The farther the polymer is from conventional hydrolysable thermoplastic linear polymers, the lower the literal risk.

Design-around by solvent/trigger

If the solvent system does not match the claim’s water-soluble biocompatible solvent concept, or if body-fluid contact does not produce a “solid or coagulated” biodegradable implant (for example, the solidification relies on photo-curing or in situ crosslinking triggered by a reagent), then the “effective to form… when said solution contacts body fluid” element becomes harder to satisfy.

Design-around by delivery device architecture

If a competitor’s delivery system is not an “outlet + ejector + hollow tube” structure as framed in Claim 9, it can attempt to avoid the kit claims. Composition claims remain unless formulation matches Claim 1/2.

Key takeaways

US 5,278,201 protects an injectable liquid polymer/solvent platform that forms a solid/coagulated biodegradable implant in situ via body-fluid contact.
The strongest literal infringement pathways are when products use:
- PLA/PGA/PCL or other polymers from Claim 2’s explicit hydrolysable list, and
- water-soluble biocompatible solvents from Claim 4/5 (especially NMP, 2-pyrrolidone, DMSO, acetone),
- with concentrations that are effective to form the implant after aqueous contact.
Kit claims require a device with outlet, ejector, and hollow tube; composition claims do not.
Dependent “space filling implant” and polymer wt% (20-75%) can narrow coverage for some products, but do not limit the broad core independent claim.

FAQs

1) Does US 5,278,201 require the implant to be drug-eluting or loaded with a biologically active agent?

No. Biologically active agents appear in dependent claims; Claim 1 and Claim 9 cover compositions/kits without requiring a drug.

2) Are the kit claims limited to specific needle or catheter types?

They require structural elements: outlet, ejector, and a hollow tube fitted to the outlet for insertion. The claims do not specify a single brand or geometry beyond those functional/structural parts.

3) Can a competitor avoid infringement by using a different solvent not listed in Claim 4/5?

To reduce literal risk, yes, but the formulation must still avoid satisfying the broader Claim 1 requirement of a pharmaceutically acceptable biocompatible water-soluble solvent that forms the implant upon body-fluid contact. The solvent must be assessed in relation to claim language and the in-situ formation mechanism.

4) If a product uses PLA or PCL but solidifies by a chemical crosslinking reaction, does that avoid the “body fluid contact” requirement?

It can, if the solidification does not rely on the claimed “body fluid contact” precipitation/coagulation of a polymer/solvent solution. The key is whether the claim’s functional condition is met as delivered.

5) What formulation range is explicitly claimed?

Only polymer wt% 20% to 75% is explicitly recited in Claim 8. Other aspects of concentration are functional (“effective to form”) rather than numerically bounded in the independent claim.

References (APA)

United States Patent 5,278,201.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0436667	⤷ Start Trial	91193	Luxembourg	⤷ Start Trial
European Patent Office	0436667	⤷ Start Trial	C300204	Netherlands	⤷ Start Trial
Austria	151257	⤷ Start Trial
Austria	162398	⤷ Start Trial
Austria	228861	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,278,201

Summary for Patent: 5,278,201